Paper Details

  1. Home
  2. Paper Details

Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.

Author: AmarKhaled, EggertKarla, KuoppamäkiMikko, LeinonenMika, LuotonenLiisa, NissinenHelena, OertelWolfgang, SkogarOrjan

Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Switching from levodopa/benserazide (LB) or levodopa/carbidopa (LC) to levodopa/carbidopa/entacapone (LCE) in Parkinson's disease (PD) patients with wearing-off resulted in significant improvement in clinical symptoms and quality of life.
Paper Details　
Original Abstract of the Article :
The study objective was to assess the efficacy, safety and feasibility of switching from levodopa/benserazide (LB) or levodopa/carbidopa (LC) to levodopa/carbidopa/entacapone (LCE) in Parkinson's disease (PD) patients with wearing-off. This was a multicenter, open-label, 6-week study; the primary ou...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00702-009-0344-4

データ提供：米国国立医学図書館（NLM）

Switch Up Your Parkinson's Treatment: Levodopa/Carbidopa/Entacapone

Greetings from Dr. Camel, your friendly neighborhood expert on all things Parkinson's disease. This study explores a common challenge for patients with Parkinson's: wearing-off, a phenomenon where medication effects fade, leaving individuals feeling like they're stuck in a sandstorm of symptoms. This study aimed to see if switching from levodopa/benserazide (LB) or levodopa/carbidopa (LC) to levodopa/carbidopa/entacapone (LCE) could help.

The researchers used a 6-week study to observe how patients responded to the switch. They found that a whopping 77% of patients reported improvement in their symptoms after switching to LCE, a significant change. It's like finding a hidden oasis in the midst of the desert, providing relief from the harsh conditions. This switch also showed improvements in other aspects of Parkinson's, including motor function and quality of life.

A New Hope for Parkinson's Patients

The results paint a hopeful picture for Parkinson's patients struggling with wearing-off. LCE seems to offer a significant benefit, helping to alleviate symptoms and improve quality of life. It's like discovering a new camel caravan route that makes the journey through the desert smoother and more enjoyable.

Improving Quality of Life

Imagine navigating the daily challenges of Parkinson's disease without the constant fear of wearing-off. This study suggests that LCE could help make life a little easier for individuals with this condition. It's like finding a sturdy camel saddle that provides a comfortable ride through the desert, allowing them to enjoy the journey without discomfort.

Dr. Camel's Conclusion

The study offers a valuable insight into Parkinson's treatment, showcasing the potential benefits of switching to LCE for patients experiencing wearing-off. It's a reminder that, even in the challenging landscape of Parkinson's, there's always hope for improvement. This is just another example of how researchers are constantly striving to find better ways to navigate the deserts of disease, bringing relief and a better quality of life to those in need.

Date :
  1. Date Completed 2010-05-20
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

20013007

DOI: Digital Object Identifier

10.1007/s00702-009-0344-4

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.